MEDICAMEQPharmaceuticals
Medicamen Biotech Ltd — PE Ratio & Valuation Analysis
₹223.30
-4.88%
Current P/E50.99xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E64.6x21.1% below avg
⚠️
60.5% Premium to Industry
MEDICAMEQ P/E 50.99x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹5.16 | ₹365 | 70.7x |
| 2024 | ₹7.50 | ₹512 | 68.3x |
| 2023 | ₹11.73 | ₹603 | 51.4x |
| 2022 | ₹12.19 | ₹831 | 68.1x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Medicamen Biotech Ltd Valuation
Medicamen Biotech Ltd (MEDICAMEQ) currently trades at 50.99x earnings. The Pharmaceuticals sector average PE is 31.77x. MEDICAMEQ commands a premium, reflecting high growth expectations. Historically, MEDICAMEQ has traded at an average PE of 64.6x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
3.39%
Dividend Yield
0.25%
More on Medicamen Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.